Taigo Kato Selected Research

Immunoglobulin A (IgA)

6/2019	Evaluation of IgA1 O-glycosylation in Henoch-Schönlein Purpura Nephritis Using Mass Spectrometry.
1/2019	Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taigo Kato Research Topics

Disease

39	Neoplasms (Cancer) 12/2022 - 02/2008
14	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 02/2008
13	Carcinoma (Carcinomatosis) 12/2022 - 07/2006
6	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2018
5	Breast Neoplasms (Breast Cancer) 07/2021 - 01/2015
4	Disease Progression 12/2022 - 01/2016
4	Urinary Bladder Neoplasms (Bladder Cancer) 10/2022 - 01/2020
4	Kidney Neoplasms (Kidney Cancer) 01/2021 - 10/2009
4	Inflammation (Inflammations) 01/2021 - 06/2014
3	Ovarian Neoplasms (Ovarian Cancer) 11/2018 - 12/2016
2	Neoplasm Metastasis (Metastasis) 05/2022 - 04/2014
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 01/2021
2	Renal Insufficiency (Renal Failure) 01/2022 - 12/2020
2	Proteinuria 01/2020 - 06/2019
2	Hematuria 01/2020 - 07/2006
2	Glomerulonephritis 01/2020 - 01/2019
2	IGA Glomerulonephritis (IGA Nephropathy) 06/2019 - 01/2019
2	Squamous Cell Carcinoma of Head and Neck 01/2019 - 01/2018
2	Hemorrhage 03/2018 - 08/2008
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2017 - 03/2016
1	Patent Ductus Arteriosus 03/2022
1	Wounds and Injuries (Trauma) 03/2022
1	Circulating Neoplastic Cells 01/2022
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2022
1	Dysbiosis 01/2022
1	Melanoma (Melanoma, Malignant) 05/2021
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2016
8	Immune Checkpoint InhibitorsIBA 01/2022 - 04/2018
7	Biomarkers (Surrogate Marker)IBA 10/2022 - 04/2018
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2017
6	Cell-Free Nucleic AcidsIBA 05/2022 - 04/2018
5	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 02/2019
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2018
3	NivolumabIBA 10/2022 - 05/2021
3	Circulating Tumor DNAIBA 05/2022 - 02/2019
3	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 01/2020
3	AntigensIBA 01/2022 - 09/2017
3	Small Interfering RNA (siRNA)IBA 08/2017 - 01/2016
3	OTS167IBA 08/2017 - 03/2016
3	Protein Kinases (Protein Kinase)IBA 03/2017 - 04/2016
2	pembrolizumabIBA 12/2022 - 10/2021
2	IpilimumabIBA 10/2022 - 01/2022
2	EnzymesIBA 10/2022 - 07/2011
2	Biological ProductsIBA 04/2022 - 07/2018
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 07/2020
2	MicroRNAs (MicroRNA)IBA 04/2021 - 04/2020
2	Methylprednisolone FDA LinkGeneric 01/2021 - 01/2020
2	HydrogenIBA 12/2020 - 01/2020
2	Immunoglobulin A (IgA)IBA 06/2019 - 01/2019
2	Pharmaceutical PreparationsIBA 07/2018 - 01/2016
2	OTS514IBA 12/2016 - 04/2016
2	Phosphotransferases (Kinase)IBA 04/2016 - 03/2016
2	DesminIBA 12/2010 - 10/2009
1	ImmunosorbentsIBA 10/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 10/2022
1	EphrinsIBA 10/2022
1	GelatinIBA 03/2022
1	Calcineurin InhibitorsIBA 01/2022
1	Everolimus FDA Link 01/2022
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022
1	SteroidsIBA 01/2022
1	TOR Serine-Threonine KinasesIBA 01/2022
1	Toll-Like Receptor 4IBA 01/2022
1	Surface Antigens (Surface Antigen)IBA 01/2022
1	NucleotidesIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	sacituzumab govitecanIBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2022
1	Histamine H1 AntagonistsIBA 01/2022
1	LigandsIBA 01/2022
1	Chemokine ReceptorsIBA 01/2022
1	Capsules (Microcapsules)IBA 01/2022
1	fexofenadine (Allegra)FDA LinkGeneric 01/2022
1	Tyrosine Kinase InhibitorsIBA 11/2021
1	AlbuminsIBA 10/2021
1	BilirubinIBA 10/2021
1	Carboplatin (JM8)FDA LinkGeneric 07/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	Insulin (Novolin)FDA Link 01/2021
1	lardIBA 01/2021
1	Granzymes (Granzyme)IBA 01/2021
1	PerforinIBA 01/2021

Therapy/Procedure

17	Therapeutics 12/2022 - 02/2008
11	Kidney Transplantation 01/2022 - 07/2009
7	Transplantation 01/2022 - 07/2009
6	Nephrectomy 10/2022 - 02/2008
5	Immunotherapy 12/2022 - 07/2018
4	Drug Therapy (Chemotherapy) 05/2022 - 07/2010
2	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 01/2018
2	Cryosurgery 05/2021 - 01/2017
2	Aftercare (After-Treatment) 01/2021 - 01/2017
2	Oral Administration 01/2021 - 01/2020
2	Castration 12/2020 - 05/2020
2	Cystectomy 08/2009 - 07/2006
2	Nephroureterectomy 08/2009 - 02/2009
1	Intravesical Administration 04/2022
1	Urinary Catheters 03/2022